NCI and Medidata extend partnership by five years to support critical oncology research

09-Oct-2023 - Last updated on 09-Oct-2023 at 11:13 GMT

A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.

This renewed commitment, spanning an additional five years, consolidates their joint efforts and underscores their dedication to advancing cancer research.

Since their partnership began in 2008, Medidata and the NCI have worked together across thousands of clinical trials with the joint goal of taking the lead in the development of promising treatments of cancer - a leading cause of mortality in the United States.

“Medidata’s long-standing partnership with the NCI represents our unwavering commitment to supporting critical oncology research,” says Joseph Schmidt, executive vice president, customer success, services, and support, at Medidata.

“It is gratifying that 90% of all oncology approvals last year in the U.S. were developed using Medidata software, and we hope to make an even bigger impact alongside the NCI over the next few years in the fight against cancer.”

The Medidata unified platform plays a vital role in supporting complex clinical trials in the healthcare and life sciences sector. The company says it has the capabilities to standardize processes, enhance data collection and support accelerated timelines. It says the goal is to bring new therapies to patients sooner that will help transform their lives. According to Medidata’s research, the solutions have been shown to help advance studies up to five months faster.

Medidata extends its expertise and clinical trial technologies to public sector research organizations that include more than 3,000 academic clinical trials, 223,000 sites and benefiting 948,000 patients.

Medidata's ongoing commitment to advancing research alongside the NCI underscores the value of partnerships in accelerating the pursuit of groundbreaking therapies that benefit patients.

NCI designated Medidata’s Rave platform as its recommended electronic data collection system for The Cancer Prevention Clinical Trials Network (CP-CTNet) to improve the consistency of data collection across a large number of institutions and trials.

The platform is an electronic data capture (EDC) and clinical data management (CDM) platform for capturing, managing and reporting of clinical, operational and safety data within a single system. It enables users to map study-related processes and user responsibilities for recording patient information.